The Zhitong Finance App learned that a federal judge in Texas recently dismissed an antitrust lawsuit filed by a compound pharmacy against LLY.US (LLY.US) and Novo Nordisk (NVO.US). The pharmacy previously accused the two companies of violating US antitrust laws by establishing exclusive partnerships with telemedicine platforms to restrict doctors from prescribing customized compound versions of their GLP-1 weight-loss drugs.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.